Subspecialties

A new study concludes that most surgical procedures used to treat optic disc pits are of no benefit – and may even be harmfu

Like bevacizumab before it, ophthalmologists are trying off-label ziv-aflibercept (formulated for systemic use) in the eye. Masterstroke or madness?

Gut microbes may be responsible for activating the T-cells that cause autoimmune uveitis

Can amniotic stem cells suppress pathologic retinal neovascularization?

Across medicine, far fewer clinical trials report positive results these days. Whether the demise of sharp scientific practices or the lack of low-hanging fruit – does it apply to ophthalmology?

Looking at vitreous samples allows us to determine which proteins are involved in the disease process, and to what degree

There’s currently an unmet need for effective interventions in early-stage retinal degenerative diseases – before vision is lost. Can three-nanosecond pulse laser therapy meet that need?

Direct visualization delivery of bevacizumab in pseudophakic eyes for the treatment of subretinal neovascularization

The path to truly effective AMD therapies is long and requires us to recognize that it’s not a single disease entity: toil and teamwork are needed to triumph

Sitting Down With...Patricia A. D’Amore, Director, Howe Laboratory; Director of Research, Schepens EyeResearch Institute, and Charles L. Schepens Professor of Ophthalmology, Harvard Medical School, Massachusetts, USA.